Key Highlights
•
A new study shows that the antiviral drug nirmatrelvir/ritonavir (Paxlovid) is safe and effective for patients with severe kidney disease and COVID-19, achieving drug levels similar to those in people with normal kidney function. This finding is crucial because it provides a much-needed treatment option for a high-risk group that was previously excluded from using this medication.
Source →
•
Researchers have identified a new, druggable mechanism in cancers where the PTEN tumor suppressor gene is missing, involving a specific phosphorylated form of the PI3Kβ protein. This discovery is significant because it points to a potential new target for treating these aggressive cancers and suggests that the existing drug dasatinib could be repurposed for this purpose.
Source →
•
A clinical trial found that adding chemotherapy to the targeted drug aumolertinib significantly improves outcomes for lung cancer patients who have specific genetic mutations in both the EGFR gene and tumor suppressor genes. This is important as it offers a more effective, personalized treatment strategy for a subgroup of patients who typically do not respond as well to targeted therapy alone.
Source →
•
A review of nearly a century of evidence confirms that aluminum salts used as adjuvants in vaccines are safe and are not linked to developmental, neurological, or autoimmune diseases. This provides strong reassurance for the public and healthcare providers, reinforcing the safety of a critical component that helps vaccines work effectively.
Source →
Stay curious. Stay informed — with
Science Briefing.
This is a one time Briefing, Upgrade to continue.
Upgrade and get 50% Off — Coupon: ERWMCWYU
